Drug Profile
B 464
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action Endotoxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory distress syndrome; Rheumatic fever; Septic shock
Most Recent Events
- 17 Nov 2006 Discontinued - Preclinical for Respiratory distress syndrome in Japan (Parenteral)
- 17 Nov 2006 Discontinued - Preclinical for Rheumatic fever in USA (Parenteral)
- 17 Nov 2006 Discontinued - Preclinical for Septic shock in Japan (unspecified route)